Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755716 · ClinicalTrials.gov registry record · Phase 3
Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study
A Phase 3 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
NCT00755716: Completed Phase 3 study, sponsored by UConn Health.
NCT00755716 is a Phase 3 study that has completed, run by UConn Health. The registered enrollment target is 57 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00755716, a Phase 3 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
Study Summary
Specific aims: 1. To obtain pilot data on 4-week continuous quit rates associated with 10 weeks of treatment with topiramate or placebo or topiramate plus nicotine patch for smoking cessation. 2. To obtain pilot data on the effects of 10 weeks of topiramate versus placebo versus combination of topiramate plus nicotine patch on nicotine withdrawal symptoms, smoking satisfaction, and adverse effects during smoking cessation. 3. To obtain pilot data on weight gain over 10 weeks with topiramate versus placebo versus combination of topiramate plus nicotine patch for smoking cessation.
Primary Outcome
The primary efficacy endpoint was CO-confirmed cigarette abstinence during the last 4 weeks of treatment.
Interventions
- DRUG Nicotine patch
- DRUG Topiramate
- DRUG Placebo (sugar pill)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2006-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT00755716 record still lists
NCT00755716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Nicotine patch is the first listed.
NCT00755716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00755716 about?
NCT00755716 is a clinical study titled "Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study". Specific aims: 1. To obtain pilot data on 4-week continuous quit rates associated with 10 weeks of treatment with topiramate or placebo or topiramate plus nicotine patch for smoking cessation. 2. To obtain pilot data on the effects of 10 weeks of topiramate versus placebo versus combination of topi...
What is the current status of trial NCT00755716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2006-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00755716?
The interventions under investigation include: Nicotine patch (DRUG), Topiramate (DRUG), Placebo (sugar pill) (DRUG).
Who is sponsoring clinical trial NCT00755716?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00755716's enrollment target sits among peer trials
57 1827th of 2000 higher than 174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia